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Abstract: Artemether–lumefantrine is one of the artemisisnin-based combination therapies 
recommended for treatment of uncomplicated falciparum malaria. The drug combination is 
highly efficacious against sensitive and multidrug resistant falciparum malaria. It offers the 
advantage of rapid clearance of parasites by artemether and the slower elimination of residual 
parasites by lumefantrine. The combination can be used in all populations except pregnant 
mothers in the first trimester where safety is still uncertain. There are still concerns about safety 
and pharmacokinetics of the drug combination in children, especially infants, pregnant mothers 
and drug interactions with mainly non-nucleoside reverse transcriptase inhibitors and protease 
inhibitors used for HIV therapy.
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Introduction
Malaria is a febrile illness caused by intracellular protozoa of the genus Plasmodium, 
and transmitted by the bite of an infected female mosquito of the genus Anopheles. 
Plasmodium species that cause disease in humans include: P . falciparum, P . vivax, 
P . malariae, P . ovale, and P . knowlesi. P . falciparum is the most prevalent and most 
virulent. Worldwide, malaria is one of the most important causes of morbidity and 
mortality. Approximately 2.2 billion people are exposed to malaria every year of whom 
about 300 to 500 million develop disease. In 2006, there were 247 million cases of 
malaria, causing nearly 1 million deaths, mostly among African children.1 Malaria deaths 
are responsible for almost 3% of the world’s disability-adjusted life years, not counting 
the considerable and imprecisely quantified burden due to morbidity and disability.2 
In addition to causing significant morbidity and mortality, malaria significantly contrib-
utes to poverty through lost productivity and economic loss on antimalarial treatment. 
African countries spend US$12 billion annually on malaria, with individual African 
families spending up to 25% of their income on malaria prevention and control. Malaria 
has slowed economic growth in African countries by 1.3% per year. As a result of the 
compounded effect over 35 years, the gross domestic product for African countries is 
now up to 32% lower than it would have been in absence of malaria.3
Reduction in malaria-associated morbidity and mortality largely depends on 
provision of prompt, effective, safe and affordable antimalarial drugs. Resistance 
to antimalarial drugs poses a significant challenge to malaria control programs in 
sub-Saharan Africa. Multi-drug resistance to sulfadoxine–pyrimethamine (SP) and 
chloroquine was described extensively in sub-Saharan Africa. The World Health Therapeutics and Clinical Risk Management 2010:6 12
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Organization (WHO) recommends use of artemisinin-based 
combination treatments (ACT) as first-line therapy. The 
ACTs combine fast-acting artemisinins with another struc-
turally unrelated and more slowly eliminated compound 
which permits elimination of residual malarial parasites.4–6 
Of the 81 countries with endemic P. falciparum, 77 have now 
adopted the WHO recommendation.7 Commonly used ACTs 
are artemether–lumefantrine (AL), amodiaquine–artesunate 
(AQAS), mefloquine–artesunate, dihydroartemisin–
piperaquine (DP) and napthoquine–artemisinin. In this 
review we provide an update on efficacy, effectiveness and 
safety of AL for treatment of uncomplicated malaria.
Pharmacology of artemether–
lumefantrine
A 6-dose regimen of artemether (20 mg) co-formulated with 
lumefantrine (120 mg) is recommended; with first and second 
doses taken 8 hours apart, the third dose taken 24 hours after 
the first and the remaining doses 12 hours apart. The 6-dose 
regimen is superior to the 4-dose regimen.8,9 Artemesinin from 
which artemether is derived is obtained from the Chinese herb 
sweet wormwood (Artemisua annua). Artemisinins have the 
most potent and rapid onset of antiparasitic activity against 
all Plasmodium species that infect humans.
Artemether acts rapidly with half-life of 1 to 3 hours, 
whereas lumefantrine has a half-life of 3 to 6 days and is 
responsible for preventing recurrent parasitemia.10 Artemether 
and lumefantrine have different modes of action and act at 
different points in the parasite life cycle.11,12 Artemether inter-
feres with parasite transport proteins, disrupts parasite mito-
chondrial function, inhibits angiogenesis and modulates host 
immune function.13 Lumefantrine is an aryl-amino alcohol14 
that prevents detoxification of heme, such that toxic heme 
and free radicals induce parasite death.12 Oral formulations of 
AL are available as tablet and dispersible formulations which 
have similar pharmacokinetic (PK) properties.15,16 Artemether 
and lumefantrine differ in rates of absorption and elimina-
tion. Artemether is rapidly absorbed reaching peak plasma 
concentrations within 2 hours post dose.11,17 It is metabolized 
rapidly by cytochrome P450 (CYP) 2B6, CYP3A4 and pos-
sibly CYP2A610 to dihydroartemisinin (DHA) which in turn 
is converted to inactive metabolites primarily by glucoroni-
dation via UGT1A1, 1A8/9 and 2B7.14 The metabolite DHA 
reaches peak plasma concentration within 2 to 3 hours post 
dosing.11 Both artemether and DHA offer potent antimalarial 
properties causing significant reduction in asexual parasite 
mass of approximately 10,000-fold per reproductive cycle, 
with prompt resolution of symptoms.18,19
Lumefantrine is absorbed and cleared more slowly, 
acting to eliminate residual parasites that may remain after 
artemether and DHA have been cleared from the body and 
thus prevent recrudescence.11,12 Lumefantrine is highly 
lipophilic, thus absorption is enhanced with a fatty meal; its 
absorption occurs 2 hours after intake reaching peak plasma 
concentration after 3 to 4 hours20 with an elimination half 
life of 4 to 10 days.20,21
Food enhances absorption of both artemether and lumefan-
trine although this effect is more apparent for lumefantrine.11,20 
Administration of AL with high-fat meal increased bioavail-
ability of both artemether and lumefantrine by 2-fold and 
16-fold respectively.11 Premji et al in an evaluation of the 
typical fat content of African diets noted that total fat intake 
is 15 to 30 g/day during breast feeding, 10 g/day in the post 
weaning phase and 30 to 60 g/day in a normal diet and this is 
adequate for optimal efficacy of lumefantrine.22
However, the effect of food on AL absorption is of con-
cern because patients with malaria usually have anorexia, 
vomiting and low food intake. Lumefantrine is metabolized 
by N-debutylation mainly by CYP3A410 to desbutyl-
lumefantrine with 5- to 8-fold higher antiparastic effect than 
lumefantrine. The key PK determinant of cure is the area 
under the concentration time curve (AUC) of the longer-
acting lumefantrine.
Efficacy and effectiveness of AL
Efficacy of the 6 dose regimen of AL judged by elimina-
tion of malaria parasites using the 28-day polymerase 
chain reaction (PCR)-corrected cure rates and resolution 
of symptoms, has been demonstrated in semi-immune and 
non-immune populations in Asia and Africa to be consis-
tently greater than 95%, with rapid parasite and symptom 
clearance and significant gametocidal effect.15,23–27 Many 
studies in Africa and Asia have demonstrated AL to be as 
efficacious as other ACTs when used in pediatric and adult 
populations with differing immunity. PCR-corrected day 
28 and day 42 cure rates range between 91% and 100% using 
evaluable patient analysis.28–62 Correction by PCR enables 
differentiation between recurrence and recrudescence of the 
initial infection from re-infection. A few cases of treatment 
failure were recorded after AL treatment, but these were 
mostly re-infections.29,32,33,38 This is of particular concern in 
areas with very intense malaria transmission where antima-
larial drugs with longer half-life may offer the advantage 
of preventing re-infection. Lumefantrine with an estimated 
elimination half-life of 4 to 10 days offers post-treatment 
antimalarial prophylaxis of up to 4 weeks. Studies showed Therapeutics and Clinical Risk Management 2010:6 13
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both AL and DP to be highly efficacious for treatment of 
uncomplicated malaria, although DP was superior to AL 
at preventing new malaria infections.33,34,38,50 In addition to 
excellent efficacy and effectiveness, AL has demonstrated 
significant gametocidal effects.34,42,48,51 A meta-analysis of 
32 randomized trials showed AL to be one of the most effec-
tive ACTs with 28-day parasitological cure rates of 97.4%.63
Effectiveness of AL may be influenced by poor adherence 
to the 3-day, 6-dose regimen and the food requirements for 
AL absorption. Clinical and parasitological responses to AL 
were similar with both supervised and unsupervised treat-
ment in Uganda.64 The supervised treatment arm received AL 
with fatty food while the unsupervised arm received AL as 
outpatient treatment with nutritional advice. Unsupervised 
treatment resulted in lower concentrations of lumefantrine 
with increased risk of early reinfection.4,64 In Uganda and 
Nigeria adherence to correct AL dose and duration prescribed 
to febrile children by community medicine distributors was 
greater than 80% and crude parasitological failure rates varied 
from 3.7% in Uganda to 41.8% in Nigeria and PCR-adjusted 
parasitological cure rate was 90.9% in Nigeria and 97.2% in 
Uganda.6 Differences in crude rates may be due to differences 
in re-infection rates. A recent study of uncomplicated malaria 
in Uganda showed adherence to AL was 94.5% compared 
to that quinine of 85.4% with high unadjusted cure rates of 
AL of 96% vs 64% for quinine.65
In multidrug-resistant areas, day 7 lumefantrine con-
centration was a useful surrogate marker for AUC and 
concentrations of less than 280 ng/mL predicted treatment 
failure.17,20 However, results from areas with lumefantrine-
sensitive parasites showed no treatment failures despite day 
7 concentrations less than 280 ng/mL in 45% of all patients, 
and re-infections occurred among patients with day 7 con-
centrations below 400 ng/mL and those who received a lower 
dose of lumefantrine per kilogram body weight.4
Safety of AL
Safety and tolerability of AL has been assessed in clinical 
trials in Asia and Africa. Most adverse events are mild or 
moderate, mostly affecting gastrointestinal and nervous 
systems; however, most are typical of the symptomatology 
of malaria or concomitant infections.15,24–27,66 Serious adverse 
events were unlikely and were unrelated or most unlikely to be 
related to study medication.15,29–31,33,34,36,38,39,41–43,46–51,53,54,67 Two 
meta-analysis concluded that AL is well tolerated, with mild 
or moderate adverse events mostly affecting gastrointestinal 
and nervous systems. Ototoxicity associated with AL has 
been reported recently in a few cases;68,69 however, this was 
not confirmed in a study that investigated hearing sensation 
following AL treatment.31 Lumefantrine possesses a similar 
chemical structure to halofantrine which is known to cause 
cardiac arrhythmia; however, safety studies have not shown 
lumefantrine to be cardiotoxic or to prolong QTc interval.67,70 
Other studies and a review of 15 trials concluded that AL did 
not cause hematological adverse events, although pre-clinical 
trials suggested the repeated exposure to AL may affect blood 
cell counts.71
Safety assessment has been conducted during treatment 
of single episodes of malaria. Safety concerns become more 
important when AL is administered over the counter, which 
commonly results in overdiagnosis and overtreatment of 
malaria, and when patients get recurrent infections requiring 
repeated treatment. Overdiagnosis of malaria is common in 
malaria-endemic areas.72 There are no standard guidelines 
for evaluating drug safety and tolerability in antimalarial 
trials.64 Establishing systems for pharmacovigilance in areas 
where AL is frequently prescribed is of utmost importance 
and several challenges exist.73
AL use in children
Vomiting, which may be due to disease-related nausea or 
taste of the medication, may influence drug intake especially 
in children. A more palatable dispersible formulation of AL 
is now available and has been shown to be as efficacious as 
the currently used crushed tablet in infants and children, and 
with similar safety and PK profile.15 Pediatric dosing of AL is 
deduced from adult-based regimens adjusted for body weight, 
with little consideration for maturational effects on drug 
absorption and metabolism. Although diet and nutritional 
status are important determinants of PK processes, drug 
responses and toxicity, there are few relevant data for AL in 
this patient group. In resource-constrained areas, children 
may not be weighed at each clinic visit and dosing in such 
settings is usually based on age as a proxy measure for weight. 
Besides research on therapeutic dose levels based on body 
weight, there is urgent need for evidence-based translation of 
weight based dosing regimens to regimens that can be based 
on age, as the majority of fevers in malaria endemic areas 
are treated with over-the-counter antimalarial drugs without 
involvement of the formal health sector. Age-based dose 
regimens are more practical than weight-based regimens, 
but will inevitably result in a greater proportion of children 
receiving either too much or too little drug. This is a particular 
concern with lumefantrine, which has a narrow therapeutic 
margin between effective and toxic concentrations. This dos-
ing consideration is especially important in malnourished, Therapeutics and Clinical Risk Management 2010:6 14
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pre-school children and during onset of puberty when 
physiological variations in bodyweight by age are greatest. 
Earlier experience with SP and DP suggests that lack of clear 
guidance on age-based dosing as part of the regulatory pro-
cess contributes to considerable variation in recommended 
age-based dose regimens,74,75 potentially resulting in poor, but 
widely used regimens, particularly for young rapidly growing 
children who bear the brunt of the malaria burden. Different 
age-based regimens are already being used in countries that 
have recently switched to ACTs. These concerns apply also 
to young infants 6 months old or of 5 kg body weight. 
Most ACTs are contra-indicated in this group because of lack 
of safety data, even though these children are at consider-
able risk. In western Kenya 50% of infants not protected by 
insecticide-treated mosquito nets had their first infection by 
3 months.76 In southern Mozambique, an estimated 9% of 
out-patient visits for uncomplicated malaria in children less 
than 5 years of age are children aged 6 months. Infants 
in endemic areas have the highest burden of severe malarial 
anemia, blood transfusions and death.77,78 Thus, programmati-
cally implemented ACTs will end up being widely used in 
children 6 months even though the label does not provide 
guidance for this age group.
Malaria and AL use in pregnancy
Pregnant women with malaria, symptomatic and asymptom-
atic alike, should be treated without delay with effective and 
safe antimalarial drugs in order to reduce risks for adverse 
outcomes for both mother and fetus.79 AL is a very attractive 
alternative because it is highly effective, acts rapidly and is 
well tolerated. However, there is insufficient information on 
safety and efficacy of ACTs in pregnancy, including exposure 
in the first trimester.79,80 Early data indicated that artemisinins 
were embryotoxic and potentially teratogenic in several animal 
species without maternal toxic effects or impaired fertility, and 
more recent studies have confirmed these findings.79
Artemisinin derivatives have shown embryo-toxic effects 
in animal reproductive toxicology studies.81 The mechanism 
of embryo-toxicity is thought to occur through depletion 
of embryonic erythroblasts causing severe anemia and cell 
damage and death due to hypoxia.81 The most sensitive time 
window for embryo-toxicity in humans is between weeks 
4 to 10. From these data ACTs are not indicated for malaria 
treatment in the first trimester of pregnancy unless no alter-
natives exist. There is increasing experience with artemisinin 
derivatives in second and third trimesters with no evidence of 
adverse outcomes in more than 1000 prospectively followed 
pregnancies.82,83 WHO Malaria Treatment Guidelines of 2006 
recommend use of ACTs in pregnant women in the second and 
third trimester of gestation. None of the studies on AL use in 
pregnancy have reported increased risk of serious maternal 
adverse events, adverse birth outcomes or neuro-developmental 
deficits. However all these studies were underpowered to detect 
rare adverse outcomes.84 Data from Sudan from a cohort of 
women who reported use of artemisinins in first trimester 
and were followed up until delivery and their babies followed 
up till 1 year of age showed that most delivered apparently 
healthy babies at full term with no congenital malformations 
and no maternal deaths, and none of the babies died during 
their first year of life.85 A prospective observational study was 
conducted recently in Zambia which evaluated safety of AL 
and SP in pregnant women who received AL and SP to treat 
symptomatic falciparum malaria. Data from 1001 pregnant 
women and fetuses/newborns indicated that the incidence 
of perinatal death, spontaneous abortion, neonatal mortality, 
premature delivery, stillbirth and low birth weight is similar 
after pregnancy exposure to AL compared to SP.86
Pregnancy has been associated with reduced plasma con-
centrations of AL which have a significant impact on treat-
ment outcome since plasma concentrations of lumefantrine, 
after elimination of artemether, are an important determinant 
of cure.87,88 A study that evaluated PK of AL in pregnant 
women with recrudescent uncomplicated multidrug resis-
tant falciparum malaria demonstrated that pregnant women 
in second and third trimester had lower concentrations of 
artemether, dihydroartemisinin and lumefantrine, and elimina-
tion of lumefantrine was more rapid than reported previously 
in non-pregnant adults.87,89 Another study that compared 
artesunate monotherapy to AL for treatment of uncomplicated 
falciparum malaria in second and third trimesters demon-
strated that the standard 6-dose AL regimen was well tolerated 
and safe but efficacy was inferior to that of 7-day artesunate 
monotherapy and was unsatisfactory for general deployment 
in this geographic area. PK parameters measured in this study 
showed low drug concentrations in later pregnancy which 
could possibly explain the poor treatment outcomes.89 There 
is need for further studies to determine the optimum dose 
regimen and efficacy of AL in pregnancy.
AL use in HIV-infected populations
Human immunodeficiency virus (HIV)-infected individu-
als are at high risk for acquiring malaria parasitemia, with 
the risk increasing as immunity declines.90–93 Evidence for 
this interaction is more consistent in pregnant women of all 
gravidities.94–96 HIV-1 infected pregnant women have a higher 
prevalence of peripheral parasitemia and placental malaria95,96 Therapeutics and Clinical Risk Management 2010:6 15
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and their infants experience higher postnatal mortality when 
both diseases are present.97,98 Therefore, offering adequate 
and efficacious antimalarial treatment and prevention is 
extremely important for this high risk group. Little is known 
about efficacy and safety of antimalarial drugs in HIV-infected 
individuals and much less on interaction between antimalarial 
and antiretroviral (ARV) drugs, and reliable data are urgently 
needed. Few studies have examined the effect of HIV infec-
tion on response to antimalarial treatment and these have 
yielded conflicting results.99–103 Most studies have shown 
that HIV-infected individuals have higher risk of experienc-
ing antimalarial treatment failure due to re-infections.101,103 
Birku et al demonstrated decreased clearance of parasites by 
artemisinin treatment in HIV-infected patients with malaria.104 
In Zambia, HIV-infected adult patients with CD4 counts of 
300/µL and below had higher risk of getting recrudescent 
malaria than HIV-infected patients with higher CD4 counts 
and HIV-uninfected patients.103 Recent studies, however, 
suggest that the threshold for an increased risk of malaria 
treatment failure (new infections or recrudescence) probably 
lies at 400 CD4 cells/µL.105,106 Following the latest WHO 
guidelines for sub-Saharan Africa this malaria vulnerable 
population should be protected by cotrimoxazole prophylaxis 
or highly active ARV therapy (HAART). There are concerns 
about safety of AL treatment in HIV-infected patients con-
comitantly receiving HAART. The standard first-line HAART 
regimens in many sub-Saharan countries where malaria is 
endemic are made up of a non-nucleoside reverse transcrip-
tase inhibitor (NNRTI) backbone with 2 nucleoside reverse 
transcriptase inhibitors (NRTI). The second-line HAART 
regimen is made up of a protease inhibitor (PI) backbone 
and 2 NRTIs. Knowledge of the metabolism of ARVs and 
AL suggests that there is potential for PK drug–drug interac-
tions.107 For example, PIs like lopinavir/ritonavir (LPV/r) 
are among the most potent inhibitors of cytochrome P450 
(typically CYP 3A4) metabolism, while NNRTIs (efavirenz 
and nevirapine) are also substrates of cytochrome P450 
and usually these two induce but occasionally efavirenz 
inhibits some P450 isoforms. Although poorly studied the 
risk of clinically significant interactions involving AL and 
ARVs is considerable108 and may result in high concentra-
tions with excessive toxicity or reduced concentrations 
with reduced efficacy and risk for development of resis-
tance to AL. The potential for interactions between ARVs 
and antimalarials have been shown in a study of healthy 
volunteers where AQAS was co-administered with the 
NNRTI efavirenz. In the first 2 study participants, the 
AUC for AQAS increased by 100% to 300% and alanine and 
aspartate transferase levels increased markedly above the 
upper limit of normal, suggesting hepatoxicity. This led to 
recommendations that AQAS should be avoided in patients 
receiving EFV . In a recent study of uncomplicated malaria in 
Uganda, treatment of HIV-infected children with AQAS was 
associated with markedly higher risk of neutropenia com-
pared with treatment of HIV-uninfected children. The risk 
of neutropenia was higher in participants with concurrent 
ARV use, especially zidovudine, and in those with a history 
of repeated doses of AQAS.109 These clinical observations 
demonstrate the need for thorough examination of the nature 
of interaction between ARVs and ACTs. An interaction is 
expected between lumefantrine and both EFV and PIs that 
could potentially lead to increased levels of lumefantrine 
(Figure 1); no data are available. The potential interactions 
with NVP are less clear but co-administration could reduce 
lumefantrine levels. A study that investigated the PKs of AL 
when administered with LPV/r in HIV-uninfected healthy 
volunteers demonstrated that the PK of lumefantrine is 
influenced by LPV/r, resulting in 2- to 3-fold increases 
in lumefantrine AUC, and trends towards decreases in 
artemether maximum concentration (Cmax) and AUC were 
noted during co-administration. Decreases in DHA AUC 
were observed during co-administration without changes in 
DHA: artemether AUC ratios. The authors concluded that 
co-administration of AL and LPV/r can be carried out for 
patients co-infected with malaria and HIV.110 This study did 
not address safety concerns with co-administration, which 
need to be considered in future studies among individuals 
living in malaria-endemic regions.
AL use in patients with co-morbidity
Treatment of tuberculosis is often a minimum of 6 months 
including 2 months of intense rifampicin-based treatment. 
Patients may concomitantly develop malaria requiring 
treatment with AL. There are currently no published data 
on interactions of rifampicin and AL. Rifampicin is a 
potent inducer of hepatic cytochrome and may influence 
the PKs of AL since both drugs are metabolized by CYP 
450.111 Theoretically co-administration of rifampicin with 
AL may result in decreased concentrations of AL resulting 
in decreased efficacy (Figure 1). Data on these PK drug 
interactions are very scarce, thus the need for more studies. 
One study evaluated effects of concomitant administration 
of AL with a potent CYP 3A4 inhibitor. Artemether, DHA, 
and lumefantrine PKs were altered by ketoconazole. AUC 
and Cmax increased for all 3 compounds and terminal half-life 
increased for artemether and DHA. None of the changes in Therapeutics and Clinical Risk Management 2010:6 16
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PK parameters were greater than the changes observed in 
healthy volunteers taking AL with a high-fat meal. There was 
no increase in observed side effects or electrocardiographic 
changes. The authors concluded that dosage adjustments of 
AL do not appear to be necessary with concomitant keto-
conazole administration.112
AL resistance
Antimalarial drug resistance has been defined as “the abil-
ity of a parasite strain to survive and/or multiply despite the 
administration and absorption of a drug given in doses equal 
to or higher than those usually recommended, but within the 
limits of tolerance of the subject.” This definition was later 
modified to specify that the drug in question must gain access 
to the parasite or the infected red blood cell for the duration 
of the time necessary for its normal action.”113 Antimalarial 
drug resistance is heightened in individuals with lower immu-
nity, such as children less than 5 years, pregnant women, 
non-immune immigrants to malarious areas, malnourished 
individuals and HIV-infected patients.113 Reduced immunity 
allows the survival of a residuum of parasites that are able 
to survive treatment, and as such reduced immunity may 
further increase the development, intensification and spread 
of resistant strains.
Resistance to artemisinins has not been confirmed 
although reduced sensitivity has been reported in China 
and Vietnam.114,115 Treatment failures occurring after AL 
treatment are thought to be due to poor absorption with 
reduced concentrations.116,117 AL selects for the P . falciparum 
multidrug resistance gene (PfMDR1) N86, the chloroquine-
susceptible allele which has been proposed as a marker for 
lumefantrine resistance.118 In Tanzania, treatment with AL 
was associated with selection of newly infecting parasites 
containing the pfmdr1 86N allele,118 which has been associ-
ated with decreased in vitro sensitivity to artemisinins and 
lumefantrine.119
Factors that lead to development, intensification and 
distribution of antimalarial drug resistance can broadly be 
classified as: factors leading to treatment failure (incor-
rect dosing regimen, non-compliance, substandard drugs 
and misdiagnosis), human behavior, parasite and vector 
biology, and drug PKs.113 In sub-Saharan Africa antimalarial 
drugs are readily available outside public health services, in 
pharmacies, drug shops and private practitioners’ clinics. 
Decreased artemether + lumefantrine 
dihydroartemisinin 
Increased dihydroartemisinin + desbutyl–
lumefantrine 
CYP 450 inhibitors  
(lopinavir–ritonavir) Increased artemether + 
lumefantrine 
Decreased 
dihydroartemisinin + 
desbutyl–lumefantrine  CYP 450 
inducers 
(rifampicin, 
efavirenz and 
nevirapine) 
artemether–lumefantrine 
Figure 1 Summary of potential pharmacokinetic interactions between artemether–lumefantrine and commonly prescribed inducers and inhibitors of CYP 450.Therapeutics and Clinical Risk Management 2010:6 17
Artemether-lumefantrine malaria treatment: an update Dovepress
submit your manuscript | www.dovepress.com
Dovepress 
Quality of antimalarials is a serious concern and counterfeits 
may be found in some of these units. In Southeast Asia half 
of the samples of artemisnins obtained from most countries 
were counterfeit.11,120 In sub-Saharan Africa substandard 
antimalarials were found in 7 countries.121,122
Conclusion
There is increasing evidence of very high efficacy and 
effectiveness of AL for treatment of uncomplicated malaria. 
Continued health education on correct use of AL and sur-
veillance of effectiveness is necessary to prevent and detect 
emergence of drug resistance. There is need to develop 
strong systems for pharmacovigilance to increase the evi-
dence base on safety of AL especially in pregnant mothers 
and infants weighing less then 5 kg. PK studies especially 
on drug interactions with ARV drugs are urgently needed.
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